Skip to main content
Log in

Langzeitbehandlung von Phantom- und Stumpfschmerzen mit Botulinumtoxin Typ A über 12 Monate

Eine erste klinische Beobachtung

Long-term treatment of phantom and stump pain with type A botulinum toxin for 1 year. First clinical observations

  • Ergebnisse & Kasuistik
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Den Einsatz von BTX A (Botox®) zur Behandlung von Phantom- und Stumpfschmerzen konnten wir kürzlich in einer ersten Pilotstudie vorstellen. In der jetzigen Kasuistik beschreiben wir nun eine erfolgreiche Langzeitbehandlung bei dieser Indikation. Wir injizierten unserem Patienten, der unter erheblichen Postamputationsschmerzen litt, je 25 IE BTX A in 4 Triggerpunkte der Stumpfmuskulatur. Die Injektion erfolgte 4-mal im Abstand von ca. 3 Monaten und ergab eine annähernd komplette Schmerzfreiheit für seine Phantom- und Stumpfschmerzen über mittlerweile mehr als ein Jahr. Die intrathekale Morphindosis konnte daraufhin auf 40% gesenkt werden, intrathekales Clonidin wurde ebenso abgesetzt wie jegliche orale Zusatzmedikation. Eine wegen der Stumpfschmerzen diskutierte, chirurgische Therapie wurde entbehrlich, und wir vermuten, dass Botulinumtoxin auch in Fällen schmerzbedingt eingeschränkter Prothesennutzung hilfreich sein könnte.

Summary

Recently we were able to describe the successful treatment of phantom pain and stump pain with botulinum toxin A in a first pilot study. This case report over a 1-year period now demonstrates that long-term treatment for this indication is possible. We injected 4×25 IU of botulinum toxin A (Botox) into trigger points of the stump muscles of a lower limb amputee who suffered from severe phantom and stump pain. With four injections performed every 3 months, the patient became almost completely pain-free, and his intrathecal morphine therapy could be reduced to 40% of the initial dose. Intrathecal clonidine was eliminated completely, as were the oral analgesics. A surgical treatment suggested for the stump pain was no longer necessary, and we suppose that botulinum toxin can also improve the tolerance of artificial limbs in cases of stump pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1.
Abb. 2.
Abb. 3.

Literatur

  1. Adler T (2001) Nachweis kortikaler Reorganisation bei Patienten mit Armamputationen und die Beziehung zu Phantomschmerzen — Eine fMRT-Studie. Z Orthop Ihre Grenzgeb 139(2):M29–30

    CAS  PubMed  Google Scholar 

  2. Aoki KR (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 [Suppl 1]:3–10

    Google Scholar 

  3. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123(6):669–76

    Article  CAS  PubMed  Google Scholar 

  4. Bone M, Critchley P, Buggy DJ (2002) Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 27(5):481–6

    Article  CAS  PubMed  Google Scholar 

  5. Breit S, Heckmann M (2000) Botulinumtoxin Ein Neurotoxin zur dermatologischen Therapie. Hautarzt 51(11):874–91

    Article  CAS  PubMed  Google Scholar 

  6. Byrnes ML, Thickbroom GW, Wilson SA, Sacco P, Shipman JM, Stell R, Mastaglia FL (1998) The corticomotor representation of upper limb muscles in writer’s cramp and changes following botulinum toxin injection. Brain 121 (Pt 5):977–88

    PubMed  Google Scholar 

  7. Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ (1997) Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp. A PET study. Brain 120 (Pt 4):571–82

    Article  PubMed  Google Scholar 

  8. Cui M, Aoki KR (2000) Botulinum-toxin A (BTX-a) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414

    Article  Google Scholar 

  9. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 96(6):3200–3205

    Article  PubMed  Google Scholar 

  10. Erbguth FJ (2003) Pain in cervical Dystonia. In: Jost WH (ed) Botulinum toxin in Painful Diseases. Pain Headache. Vol.14. Karger, Basel, S 54–70

  11. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol113(3):400–404

    Google Scholar 

  12. Flor H, Elbert T, Knecht S (1995) Phantom-limb pain as a perceptual correlate of cortical reorganisation following arm amputation. Nature 375:482–484

    CAS  PubMed  Google Scholar 

  13. Flor H, Bierbaumer N (2000) Phantom limb pain : cortical plasticity and novel therapeutic approaches. Curr Opin Anaesthesiol 13:561–564

    Article  Google Scholar 

  14. Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A. (2000) Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48(1):20–26

    CAS  PubMed  Google Scholar 

  15. Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45(4):712–717

    CAS  PubMed  Google Scholar 

  16. Gross D (1981) Kontralaterale Lokalanästhesie zur Behandlung von Stumpf – und Phantomschmerzen. MMW Munch Med Wochenschr 123(36):1332

    CAS  PubMed  Google Scholar 

  17. Hawley PH (2002) Botulinum toxin for severe anorectal pain. J Pain Symptom Manage 24(1):11–13

    Article  PubMed  Google Scholar 

  18. Huse E, Larbig W, Flor H, Birbaumer N (2001) The effect of opioids on phantom limb pain and cortical reorganization. Pain 90(1–2):47–55

    Google Scholar 

  19. Jaeger H, Maier C (1992) Calcitonin in phantom limb pain: a double-blind study. Pain 48(1):21–7

    Article  CAS  PubMed  Google Scholar 

  20. Janicki PK, Habermann E (1983) Tetanus and botulinum toxins inhibit, and black widow spider venom stimulates the release of methionine-enkephalin-like material in vitro. J Neurochem 41(2):395–402

    CAS  PubMed  Google Scholar 

  21. Jost WH (1995) Analfissuren. In: Deuschl G (Hrsg) Botulinumtoxin-Forum 1995. Wissenschaftverlag Wellingsbüttel, Hamburg, S 31–36

  22. Kanovsky P, Streitova H, Dufek J, Znojil V, Daniel P, Rektor I (1998) Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. Mov Disord 13(1):108–117

    CAS  PubMed  Google Scholar 

  23. Kelm S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduktion von Schmerzen und Muskelanspannung durch Botulinum-Toxin A Nervenarzt 72(4):302–306

    Google Scholar 

  24. Kern U, Martin C, Scheicher S, Müller H (2003) Botulinum-Toxin-A in der Behandlung von Phantomschmerzen. Eine Pilotstudie Schmerz 17(2):117–124

    Article  CAS  Google Scholar 

  25. Kern U, Göhmann D, Martin C, Scheicher S (2003) Botulinumtoxin B zur Therapie von Phantom- und Stumpfschmerzen. Posterpräsentation P766, 76. Kongress Deutsche Gesellschaft für Neurologie mit Fortbildungsakademie Hamburg, September 2003. Akt Neurol [Suppl 1]:1–236

  26. Kew JJ, Ridding MC, Rothwell JC et al. (1994) Reorganization of cortical blood flow and transcranial magnetic stimulation maps in human subjects after upper limb amputation. J Neurophysiol 72(5):2517–2524

    CAS  PubMed  Google Scholar 

  27. Konrad H, Karamfilov T (2000) Botulinum toxin A Therapie bei Stumpfdermatitis durch fokale Hyperhidrosis. Z Hautkrankh 75(6):390

    Google Scholar 

  28. Machin P, de C Williams AC (1998) Stiff upper lip: coping strategies of World War II veterans with phantom limb pain. Clin J Pain 14(4):290–294

    Article  CAS  PubMed  Google Scholar 

  29. Moreno-Lopez B, Pastor AM, de la Cruz RR, Delgado-Garcia JM (1997) Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology 48(2):456–464

    CAS  PubMed  Google Scholar 

  30. Naumann M, Flachenecker P, Brocker EB, Toyka KV, Reiners K (1997) Botulinum toxin for palmar hyperhidrosis. Lancet 349(9047):252

    CAS  Google Scholar 

  31. Nixdorf DR, Heo G, Major PW (2002) Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 99(3):465–473

    Article  CAS  PubMed  Google Scholar 

  32. Pohjolainen T (1991) A clinical evaluation of stumps in lower limb amputees. Prosthet Orthot Int 15(3):178–184

    CAS  PubMed  Google Scholar 

  33. Purkiss J, Welch M, Doward S, Foster K (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59(11):1403–1406

    Google Scholar 

  34. Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19(4):488–496

    Article  CAS  PubMed  Google Scholar 

  35. Simanski C, Bathis H, Bouillon B, Koch-Epping G, Tiling T (2001) Therapiekonzept zur Verhinderung der Phantomschmerzchronifizierung nach traumatischer Armplexusläsion. Unfallchirurg 104(7):659–664

    Article  CAS  PubMed  Google Scholar 

  36. Wiegand H, Wellhoner HH (1977) The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 298(3):235–238

    CAS  PubMed  Google Scholar 

  37. Wollina U, Konrad H, Graefe T, Thiele J (2000) Botulinum toxin A for focal hyperhidrosis in leg amputees: a case report. Acta Derm Venereol 80(3):226–227

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to U. Kern.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kern, U., Martin, C., Scheicher, S. et al. Langzeitbehandlung von Phantom- und Stumpfschmerzen mit Botulinumtoxin Typ A über 12 Monate. Nervenarzt 75, 336–340 (2004). https://doi.org/10.1007/s00115-003-1657-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-003-1657-4

Schlüsselwörter

Keywords

Navigation